Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure

被引:0
|
作者
Lukas Gerasimavicius
Benjamin J. Livesey
Joseph A. Marsh
机构
[1] University of Edinburgh,MRC Human Genetics Unit, Institute of Genetics & Cancer
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Most known pathogenic mutations occur in protein-coding regions of DNA and change the way proteins are made. Taking protein structure into account has therefore provided great insight into the molecular mechanisms underlying human genetic disease. While there has been much focus on how mutations can disrupt protein structure and thus cause a loss of function (LOF), alternative mechanisms, specifically dominant-negative (DN) and gain-of-function (GOF) effects, are less understood. Here, we investigate the protein-level effects of pathogenic missense mutations associated with different molecular mechanisms. We observe striking differences between recessive vs dominant, and LOF vs non-LOF mutations, with dominant, non-LOF disease mutations having much milder effects on protein structure, and DN mutations being highly enriched at protein interfaces. We also find that nearly all computational variant effect predictors, even those based solely on sequence conservation, underperform on non-LOF mutations. However, we do show that non-LOF mutations could potentially be identified by their tendency to cluster in three-dimensional space. Overall, our work suggests that many pathogenic mutations that act via DN and GOF mechanisms are likely being missed by current variant prioritisation strategies, but that there is considerable scope to improve computational predictions through consideration of molecular disease mechanisms.
引用
收藏
相关论文
共 50 条
  • [1] Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure
    Gerasimavicius, Lukas
    Livesey, Benjamin J.
    Marsh, Joseph A.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [2] NALCN channelopathies: Distinguishing gain-of-function and loss-of-function mutations
    Bend, Eric G.
    Si, Yue
    Stevenson, David A.
    Bayrak-Toydemir, Pinar
    Newcomb, Tara M.
    Jorgensen, Erik M.
    Swoboda, Kathryn J.
    NEUROLOGY, 2016, 87 (11) : 1131 - 1139
  • [3] Analysis of sperm galactosyltransferase through gain-of-function and loss-of-function mutations
    Shur, B
    Lu, QX
    Shi, XD
    Paruchuru, K
    Miller, D
    MOLECULAR BIOLOGY OF THE CELL, 1998, 9 : 7A - 7A
  • [4] Using SIFT and PolyPhen to Predict Loss-of-Function and Gain-of-Function Mutations
    Flanagan, Sarah E.
    Patch, Ann-Marie
    Ellard, Sian
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2010, 14 (04) : 533 - 537
  • [5] Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations
    Katsumura, Koichi Ricardo
    Liu, Peng
    Mehta, Charu
    Hewitt, Kyle J.
    Soukup, Alexandra
    de Andrade, Isabela J. Fraga
    Ranheim, Erik A.
    Johnson, Kirby D.
    Bresnick, Emery H.
    BLOOD, 2019, 134
  • [6] Mutant p53 oncogenicity: dominant-negative or gain-of-function?
    Stein, Yan
    Aloni-Grinstein, Ronit
    Rotter, Varda
    CARCINOGENESIS, 2020, 41 (12) : 1635 - 1647
  • [7] Prediction of gain-of-function and loss-of-function mutations using In Silico Bioinformatics Tools
    Ghosh, A.
    Navarini, A.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E41 - E41
  • [8] HETEROZYGOUS FRAMESHIFT MUTATIONS OF TP53 IN HUMAN BREAST CANCER CAUSE DOMINANT-NEGATIVE AND GAIN-OF-FUNCTION EFFECTS THROUGH PROTEIN AGGREGATION
    Xu, J.
    Couceiro, J.
    Rousseau, F.
    Schymkowitz, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 56 - 56
  • [9] Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa
    Mendes, Hugo F.
    Cheetham, Michael E.
    HUMAN MOLECULAR GENETICS, 2008, 17 (19) : 3043 - 3054
  • [10] JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
    Nils Ott
    Laura Faletti
    Maximilian Heeg
    Virginia Andreani
    Bodo Grimbacher
    Journal of Clinical Immunology, 2023, 43 : 1326 - 1359